Internal Medicine, Endocrinology, Diabetes, & Metabolism · East Hartford, CT
NPI
1710188685
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
893 Main St Ste 202
East Hartford, CT, 06108
Phone (860) 247-2137
Groups this clinician bills Medicare through
Medicare paid, 2024
$76K
1,472 services
Medicare patients, 2024
307
Average age 75
Drug cost, 2024
$3.2M
4,770 prescriptions
Company payments, 2025
$3,163
From 45 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Adarsh Jha was code 82962 (clinical chemistry), 328 times for 113 patients. In total Adarsh Jha billed 1,472 services in 18 codes, and Medicare paid $76K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-06-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 82962 Clinical Chemistry | Office | 328 | 113 | $3.19 | $1,047 |
| 99214 Office E&M - Established | Office | 321 | 175 | $97.85 | $31K |
| 83036 Blood Count | Office | 253 | 109 | $9.48 | $2,400 |
| 95251 Test - Miscellaneous | Office | 188 | 64 | $27.78 | $5,224 |
| 99213 Office E&M - Established | Office | 165 | 127 | $70.93 | $12K |
| 99215 Office E&M - Established | Office | 82 | 51 | $140.05 | $11K |
| 76536 Ultrasound - Nonspecific | Office | 52 | 50 | $81.67 | $4,247 |
| 99204 Office E&M - New | Office | 31 | 31 | $137.60 | $4,266 |
| 96372 Injection Administration | Office | 17 | 12 | $11.94 | $203 |
| 99205 Office E&M - New | Office | 15 | 14 | $164.27 | $2,464 |
By year: 2022 $78K for 1,448 services; 2023 $72K for 1,394 services; 2024 $76K for 1,472 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 328 | 113 | $3.19 | $1,047 |
| 83036 Blood Count | 253 | 109 | $9.48 | $2,400 |
Medicare prescription drug claims, 2024
In 2024, the drug Adarsh Jha prescribed most often to Medicare patients was Ozempic (Semaglutide), with 363 prescriptions and refills. In total Adarsh Jha wrote 4,770 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 363 | 707 | 75 | $687K |
| Levothyroxine Sodium Generic | 361 | 995 | 103 | $4,292 |
| Metformin Hcl Er Metformin Hcl | 281 | 755 | 89 | $3,687 |
| Synthroid Levothyroxine Sodium | 253 | 689 | 62 | $28K |
| Jardiance Empagliflozin | 223 | 533 | 55 | $316K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 173 | 441 | 70 | $24K |
| Alendronate Sodium Generic | 155 | 434 | 53 | $1,073 |
| Prolia Denosumab | 152 | 906 | 95 | $262K |
| Tresiba Flextouch U-200 Insulin Degludec | 148 | 402 | 41 | $218K |
| Metformin Hcl Generic | 144 | 356 | 36 | $877 |
| Humalog Kwikpen U-100 Insulin Lispro | 130 | 346 | 49 | $36K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 109 | 301 | 36 | $16K |
| Novolog Flexpen Insulin Aspart | 104 | 265 | 41 | $30K |
| Tresiba Flextouch U-100 Insulin Degludec | 102 | 281 | 28 | $65K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 85 | 202 | 33 | $23K |
Brand drugs: 2,816 claims; generic drugs: 1,544 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Adarsh Jha $3,163 ($3,163 in general payments such as food, travel and fees) from 45 companies. The largest payer was Abbott Laboratories with $344.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 14 | $344 |
| Novo Nordisk Inc NVO | 22 | $284 |
| Amgen Inc. AMGN | 13 | $274 |
| Lilly USA, LLC LLY | 8 | $210 |
| Mannkind Corporation MNKD | 4 | $157 |
| Neurocrine BioSciences, Inc. NBIX | 5 | $148 |
| Exact Sciences Corporation EXAS | 5 | $145 |
| Radius Health, Inc. | 4 | $117 |
| GlaxoSmithKline, LLC. GSK | 4 | $98.27 |
| Verona Pharma, Inc. VRNA | 4 | $86.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.